Endocrine

Carcinoid syndrome: diagnosis and management

Clinical Overview and When to Suspect Carcinoid Syndrome

— Midgut NETs (jejunum, ileum, appendix, proximal colon) → secrete into portal circulation → must have liver metastases to cause syndrome.

— Bronchial, ovarian, or retroperitoneal NETs → drain into systemic circulation → can cause syndrome without liver mets.

— Incidence of NETs rising (~7/100,000); only ~10–20% of all NETs ever develop carcinoid syndrome.

— Median age at diagnosis 55–65; often 5–7 year diagnostic delay because flushing/diarrhea is misattributed to menopause, IBS, or rosacea.

— Episodic dry, non-sweaty flushing of face/neck triggered by alcohol, cheese, stress, or exertion.

— Secretory diarrhea that persists with fasting; large-volume, watery, occurs 4–12 times/day.

— New right-sided murmur (TR, PS) in a patient with chronic diarrhea or unexplained weight loss.

— Wheezing without classic asthma history, especially with flushing.

— Hepatomegaly + nodular liver lesions found incidentally on imaging.

Carcinoid syndrome = constellation of vasoactive symptoms (flushing, diarrhea, bronchospasm, right-sided valvular disease) caused by systemic release of serotonin, histamine, tachykinins, and prostaglandins from a well-differentiated neuroendocrine tumor (NET).

Pathophysiologic gate: vasoactive mediators must bypass hepatic first-pass metabolism to cause systemic symptoms.

Epidemiology and timing:

When to suspect on Step 3:

Board pearl: The triad flushing + diarrhea + right-heart murmur should immediately trigger a 24-hour urine 5-HIAA, regardless of whether the patient was previously labeled with IBS or rosacea. Carcinoid is the classic "long latency" Step 3 outpatient miss — chart-review questions love a patient with years of "IBS" who now has cardiac findings.

Most originate from enterochromaffin cells; small bowel primary is most common cause of the clinical syndrome.

Presentation Patterns and Key History

— Midgut tumor flush: dry, pink-to-red, face/neck/upper chest, lasts 30 seconds to a few minutes.

— Foregut (bronchial/gastric) flush: prolonged (hours), purplish, wheal-like, often with lacrimation, salivation, facial edema — histamine-mediated.

— Triggers: ethanol, tyramine-rich foods (aged cheese, smoked meats), spicy food, exercise, emotional stress, anesthesia induction, palpation of tumor.

— Persists with NPO status (distinguishes from osmotic).

— Often associated with cramping and urgency; nocturnal stools common.

— Can cause electrolyte loss → hypokalemia, metabolic acidosis, dehydration.

— Duration of symptoms (often years), prior IBS/rosacea/menopause labels.

— Family history: MEN1 (parathyroid + pituitary + pancreatic NET) — relevant for foregut carcinoids.

— Surgical/anesthesia history (prior carcinoid crisis?).

— Medications: SSRIs can worsen serotonin symptoms; MAOIs contraindicated.

Cutaneous flushing (~85%) — the most common and most discriminating symptom.

Diarrhea (~70%) — secretory, watery, large-volume.

Bronchospasm/wheezing (~15%) — may be misdiagnosed as asthma; suspect when paired with flushing.

Carcinoid heart disease (~20–50% of syndrome patients) — exertional dyspnea, fatigue, peripheral edema, ascites from right heart failure.

Pellagra-like symptoms — dermatitis, diarrhea, dementia: tumor diverts tryptophan → serotonin, depleting niacin precursors.

Mesenteric fibrosis — postprandial pain, partial small-bowel obstruction, mesenteric ischemia.

Key history to elicit:

Key distinction: Pheochromocytoma flushing is rare — pheo classically causes pallor with sweating. Carcinoid flush is dry without diaphoresis; pheo paroxysms are wet with hypertension. This dry-vs-wet, pink-vs-pale split is a recurring Step 3 buzzword.

Physical Exam Findings and Hemodynamic Assessment

— Often appears well between episodes; flushing may be reproduced by alcohol challenge in clinic (not recommended on boards).

— Cachexia, temporal wasting in advanced disease.

— Pellagra signs: hyperpigmented, scaly dermatitis on sun-exposed areas; glossitis; cognitive slowing.

— Plaque-like fibrous deposits on right-sided endocardium/valves from high serotonin exposure before pulmonary metabolism.

— Tricuspid regurgitation (most common): holosystolic murmur at LLSB, increases with inspiration (Carvallo sign), prominent V-waves in JVP, pulsatile liver.

— Pulmonic stenosis: crescendo-decrescendo systolic murmur at 2nd left ICS, soft/absent P2.

— Left-sided lesions only if patent foramen ovale or bronchial primary.

— Signs of right heart failure: elevated JVP, hepatomegaly, ascites, peripheral edema.

— Hepatomegaly (often nodular, firm) suggests metastases.

— Mesenteric mass occasionally palpable; high-pitched bowel sounds in partial SBO.

— Right upper quadrant tenderness if rapid hepatic capsular stretch.

— Vitals during a flush: BP may drop (vasodilatation from kinins/tachykinins) rather than rise — opposite of pheo.

— Tachycardia common.

— Carcinoid crisis = profound hypotension/HTN swings, severe bronchospasm, arrhythmia, often precipitated by anesthesia, tumor manipulation, or chemoembolization.

General appearance:

Skin: telangiectasias on cheeks/nose (chronic flushing), cyanotic flush in foregut tumors, leonine facies in long-standing disease.

Cardiovascular — Carcinoid heart disease (Hedinger syndrome):

Pulmonary: wheezing during flushing episode; clear between attacks.

Abdomen:

Hemodynamic assessment:

Step 3 management: Any new murmur in a NET patient warrants transthoracic echocardiogram + NT-proBNP; carcinoid heart disease is the leading cause of death in carcinoid syndrome and is silent until advanced — screen at diagnosis and annually.

Diagnostic Workup — Initial Labs and Biomarkers

— 5-HIAA is the terminal metabolite of serotonin; elevation >2× upper limit is highly specific.

— Sensitivity ~70%, specificity ~90% for midgut carcinoid syndrome.

— Dietary prep critical (3 days before and during collection): avoid serotonin-rich foods — bananas, pineapple, kiwi, plums, tomatoes, avocado, eggplant, walnuts, pecans.

— Hold medications: acetaminophen, guaifenesin, salicylates, L-dopa, MAOIs, SSRIs can all interfere (false positives or negatives).

— Foregut tumors may be 5-HIAA negative (lack aromatic amino acid decarboxylase); rely on plasma chromogranin A and tumor imaging.

— Elevated in ~80% of NETs.

— Many false positives: PPIs/H2 blockers (most common pitfall — hold for 2 weeks), atrophic gastritis, renal failure, heart failure, chronic liver disease, IBD.

— Useful for monitoring trends, not initial diagnosis in isolation.

— CBC, CMP — look for hypokalemia, non-anion-gap acidosis from diarrhea, hypoalbuminemia.

— LFTs — elevations suggest hepatic metastases.

— Niacin level / consider empiric supplementation if pellagra signs.

— NT-proBNP — elevated in carcinoid heart disease; useful screening adjunct to echo.

— TSH (rule out hyperthyroid flushing), tryptase (mastocytosis), metanephrines (pheo).

24-hour urine 5-hydroxyindoleacetic acid (5-HIAA): the cornerstone screening test.

Plasma 5-HIAA: newer assay, no dietary restriction, gaining acceptance — useful when 24-hour collection impractical.

Chromogranin A (CgA): general NET marker.

Neuron-specific enolase (NSE): alternative marker, more useful in poorly differentiated NETs.

Routine labs:

ECG: nonspecific; may show right heart strain in advanced carcinoid heart disease.

Board pearl: A patient on omeprazole with "elevated chromogranin A" is the classic Step 3 distractor — stop the PPI for 2 weeks and recheck before initiating an expensive NET workup. False-positive CgA from PPI use is the most common spurious result.

Diagnostic Workup — Advanced and Confirmatory Studies

— Multiphase CT abdomen/pelvis with IV contrast (arterial + portal phases): identifies primary, mesenteric mass with characteristic "spoke-wheel" desmoplastic reaction, liver metastases (hypervascular on arterial phase).

— MRI liver with gadolinium is more sensitive than CT for hepatic metastases; preferred for surveillance and pre-resection planning.

— ⁶⁸Ga-DOTATATE PET/CT is the gold standard: targets somatostatin receptor type 2 (SSTR2), expressed on >80% of well-differentiated NETs.

— Sensitivity >90%, far superior to the older ¹¹¹In-octreotide (OctreoScan), which is now largely obsolete.

— Identifies occult primaries, distant mets, and predicts response to somatostatin analogs (SSAs) and peptide receptor radionuclide therapy (PRRT).

— Hold long-acting SSAs ~4 weeks before scan to avoid receptor blockade.

— Upper endoscopy for foregut (gastric, duodenal) primaries; EUS for pancreatic NETs.

— Colonoscopy + ileoscopy for terminal ileal primaries.

— Video capsule or push enteroscopy if small bowel primary suspected but not localized.

— Core or excisional biopsy with immunohistochemistry: synaptophysin (+), chromogranin (+), CD56 (+).

— Grade by mitotic count and Ki-67 proliferation index:

— G1: Ki-67 <3%

— G2: Ki-67 3–20%

— G3: Ki-67 >20% (poorly differentiated / NEC)

— Grade drives prognosis and treatment selection.

Once biochemical evidence supports carcinoid, the goal is tumor localization + staging.

Cross-sectional imaging — first-line anatomic:

Functional imaging — first-line molecular:

FDG-PET: reserved for poorly differentiated/high-grade NETs (Ki-67 >20%), which are SSTR-negative and FDG-avid.

Endoscopy:

Tissue diagnosis (essential — guides therapy):

Echocardiography: mandatory at diagnosis if symptomatic — assess tricuspid/pulmonic valves, RV size/function; repeat annually or with new symptoms.

Key distinction: DOTATATE PET = well-differentiated, low-grade NET; FDG-PET = high-grade/poorly differentiated NEC. Some G2/G3 tumors are dual-positive and warrant both scans for full mapping.

Risk Stratification and First-Line Management Logic

— G1/G2 well-differentiated → somatostatin analogs (SSAs) as backbone.

— G3 poorly differentiated NEC → platinum-based chemotherapy (cisplatin/etoposide), behaves like small-cell carcinoma.

— Localized primary + resectable nodes → curative surgery; perioperative SSA coverage.

— Limited liver metastases → consider hepatic resection, ablation (RFA, microwave), or transplant in highly selected young patients.

— Diffuse unresectable hepatic disease → SSAs + locoregional liver-directed therapy (TAE/TACE, ⁹⁰Y radioembolization) + systemic options.

— Extrahepatic metastases → systemic therapy primary; PRRT if SSTR-positive.

— All symptomatic carcinoid syndrome patients receive long-acting SSAs regardless of tumor burden — they control hormonal symptoms AND have antiproliferative benefit (PROMID, CLARINET trials).

— Add telotristat ethyl if diarrhea persists despite SSAs.

— Ki-67, tumor grade, liver tumor burden, presence of carcinoid heart disease, 5-HIAA levels.

— 5-year survival: localized ~95%, regional ~80%, distant ~55–70% (improving with modern therapy).

— NET-experienced centers improve survival.

— Team: medical oncology, surgical oncology, interventional radiology, endocrinology, cardiology, nuclear medicine, nutrition.

Management hinges on three axes: tumor grade, tumor burden/resectability, and symptom severity.

Grade (Ki-67) drives systemic choice:

Resectability decision tree (well-differentiated):

Symptom-directed parallel track:

Prognostic markers:

Multidisciplinary referral is the standard of care:

Step 3 management: Once a patient has biochemical + imaging confirmation of carcinoid syndrome, the immediate outpatient steps are: (1) start a long-acting SSA (octreotide LAR or lanreotide), (2) obtain baseline echocardiogram and NT-proBNP, (3) refer to a high-volume NET center for multidisciplinary planning, (4) counsel on flush triggers (alcohol, tyramine foods, stress). All four belong on the order set in the same visit.

Pharmacotherapy — First-Line Drug Regimen

— Octreotide LAR 20–30 mg IM every 4 weeks, or Lanreotide 120 mg deep SC every 4 weeks.

— Mechanism: bind SSTR2/SSTR5 → inhibit secretion of serotonin, histamine, other peptides; antiproliferative via cell-cycle arrest.

— Symptom control: 70–80% reduction in flushing/diarrhea.

— Bridge therapy: short-acting subcutaneous octreotide 100–200 mcg TID for the first 2 weeks until depot reaches steady state, and as rescue for breakthrough symptoms.

— Side effects: steatorrhea (pancreatic enzyme insufficiency — supplement lipase), cholelithiasis (~50% form sludge/stones — screen with RUQ ultrasound), hyperglycemia, B12 deficiency, sinus bradycardia, injection-site nodules.

— Oral tryptophan hydroxylase inhibitor → blocks serotonin synthesis at its source.

— Indicated for SSA-refractory diarrhea; reduces stool frequency by 1–2/day.

— Watch for depression (rare), elevated LFTs, constipation.

— Diarrhea: loperamide, diphenoxylate-atropine, cholestyramine (if bile-acid component after ileal resection).

— Flushing: H1 + H2 blockers (especially for foregut/histamine-mediated flushes); avoid sympathomimetics.

— Bronchospasm: inhaled ipratropium preferred; avoid epinephrine/beta-agonists during carcinoid crisis (can paradoxically worsen mediator release).

— Niacin replacement for pellagra symptoms.

Somatostatin analogs (SSAs) = cornerstone of medical therapy.

Telotristat ethyl 250 mg PO TID with food.

Interferon-alpha: older option, modest symptom and antiproliferative effect; limited use due to flu-like side effects, depression, cytopenias.

Adjunctive symptom drugs:

Drugs to avoid: SSRIs (worsen serotonin burden), MAOIs, sympathomimetic decongestants, succinylcholine and morphine in acute crisis (histamine release).

Board pearl: A NET patient on long-acting octreotide who develops new RUQ pain → think SSA-induced cholelithiasis. Many centers perform prophylactic cholecystectomy at the time of primary tumor resection because incident gallstones complicate future surgeries. Baseline gallbladder ultrasound before starting SSAs is reasonable.

Advanced Therapies — PRRT, Liver-Directed, and Chemotherapy

— ¹⁷⁷Lu-DOTATATE (Lutathera): 4 infusions every 8 weeks.

— Indicated for progressive, SSTR-positive, well-differentiated GEP-NETs after SSA failure (NETTER-1 trial showed major PFS benefit in midgut NETs).

— Toxicities: nausea (premedicate with antiemetics + amino acid infusion for renal protection), cytopenias, secondary MDS/leukemia (~2%), nephrotoxicity.

— Requires confirmed avid uptake on DOTATATE PET.

— Bland transarterial embolization (TAE) or chemoembolization (TACE) with doxorubicin/streptozocin.

— ⁹⁰Y radioembolization (TARE) — selective internal radiation.

— Radiofrequency or microwave ablation for ≤5 lesions <3 cm.

— Hepatic resection / debulking if >70% of tumor burden can be removed — improves symptoms and survival.

— Pre-procedure octreotide infusion (50–100 mcg/hr) mandatory to prevent carcinoid crisis from mediator release.

— Everolimus (mTOR inhibitor) 10 mg daily — approved for progressive NETs (RADIANT trials); SE: stomatitis, hyperglycemia, pneumonitis.

— Sunitinib 37.5 mg daily — approved for pancreatic NETs specifically.

— Capecitabine + temozolomide (CAPTEM) — preferred for pancreatic NETs and progressive G2 disease.

— Cisplatin + etoposide — first-line for G3 poorly differentiated NEC.

— Streptozocin-based regimens largely supplanted.

— Severe flushing, bronchospasm, hypotension or labile BP, tachyarrhythmias during surgery, anesthesia, biopsy, or embolization.

— IV octreotide bolus 500–1000 mcg, then 50–200 mcg/hr infusion.

— IV fluids, avoid catecholamines (worsen mediator release) — use vasopressin or phenylephrine if pressor needed.

— Correct electrolytes, treat bronchospasm with ipratropium, glucocorticoids may help.

Peptide receptor radionuclide therapy (PRRT):

Liver-directed therapies (for hepatic-dominant disease):

Targeted therapy:

Cytotoxic chemotherapy:

Carcinoid crisis management (CCS-relevant):

CCS pearl: Before any planned procedure (surgery, anesthesia induction, hepatic embolization, biopsy of a NET met) start prophylactic IV octreotide ≥12 hours preop and continue intraop. Forgetting this prophylaxis is a classic Step 3 CCS error that triggers intraoperative carcinoid crisis.

Special Populations — Elderly and Renal/Hepatic Impairment

— Carcinoid is frequently diagnosed in this group; symptoms often dismissed as "IBS of aging" or menopause/perimenopause flush — maintain high suspicion.

— SSAs are well tolerated in elderly; no dose adjustment for age alone.

— Monitor for symptomatic bradycardia (octreotide can lower HR 5–10 bpm) especially if on beta-blockers, AV-nodal agents, or with baseline conduction disease — check ECG at baseline and 3 months.

— Higher risk of cholelithiasis complications; lower threshold for gallbladder imaging.

— Pellagra (B3 deficiency) more common; baseline malnutrition magnifies tryptophan diversion — supplement niacin 100 mg/day empirically in advanced disease.

— Polypharmacy: review for SSRIs (commonly prescribed for "anxiety" — worsen serotonin burden), interacting QT-prolonging agents.

— Consider frailty index before PRRT or hepatic embolization.

— Octreotide and lanreotide are renally excreted but generally do not require dose adjustment until CrCl <30 mL/min, where dose intervals may be extended or doses reduced.

— PRRT (¹⁷⁷Lu-DOTATATE): CrCl <50 mL/min is a relative contraindication; mandatory co-infusion of amino acids (lysine + arginine) to competitively block proximal tubular reabsorption and minimize nephrotoxicity.

— Telotristat: no specific renal adjustment, but limited data in severe CKD.

— Chromogranin A is falsely elevated in renal failure — interpret with caution; rely on 5-HIAA and imaging instead.

— Liver metastases are the rule, not exception, in midgut carcinoid syndrome → most patients have some degree of hepatic dysfunction.

— Everolimus, sunitinib, capecitabine, temozolomide all require dose reduction in Child-Pugh B/C.

— Avoid hepatotoxic drugs (acetaminophen >2 g/day, statins if transaminases >3× ULN).

— Liver-directed therapy contraindicated if portal vein thrombosis, total bilirubin >2 mg/dL, or main portal flow compromised.

Elderly (≥65):

Renal impairment:

Hepatic impairment:

Step 3 management: In a NET patient with CKD stage 4–5, substitute or stop PPIs before drawing chromogranin A (false elevation compounded by renal clearance issues), and shift surveillance to 24-hour 5-HIAA + DOTATATE PET imaging rather than serial CgA trends.

Special Populations — Pregnancy, Pediatrics, and MEN Syndromes

— Rare overlap (NETs peak after reproductive years), but increasing as childbearing delayed.

— Symptoms may worsen due to volume shifts and uterine compression of mesenteric mass.

— SSAs (octreotide, lanreotide) are pregnancy category C — limited data but generally continued if benefit outweighs risk; symptom control prevents carcinoid crisis during labor.

— Avoid: PRRT (teratogenic, contraindicated), everolimus (embryotoxic), chemotherapy in 1st trimester.

— Delivery planning: multidisciplinary team; prophylactic IV octreotide infusion during labor and 48 h postpartum; avoid morphine, succinylcholine; use neuraxial anesthesia preferentially.

— Breastfeeding: SSAs minimally excreted; case-by-case decision.

— NETs rare in children; appendiceal carcinoid is the most common GI malignancy of childhood, usually incidentally found at appendectomy.

— Most pediatric appendiceal carcinoids <2 cm — appendectomy alone is curative, no further therapy needed.

— Right hemicolectomy indicated for tumors >2 cm, base of appendix involvement, mesoappendix invasion, lymphovascular invasion, or positive margins.

— Autosomal dominant; mutation in MEN1 gene (menin) on 11q13.

— Triad: 3 P's — Parathyroid hyperplasia (primary hyperparathyroidism, ~95%), Pancreatic NETs (gastrinoma, insulinoma), Pituitary adenomas (prolactinoma most common).

— Associated with foregut carcinoids: thymic, bronchial, gastric (type II ECL-cell).

— Thymic carcinoid in MEN1 men who smoke is highly aggressive; annual chest CT screening recommended.

— Genetic counseling + cascade testing for first-degree relatives; annual biochemical and imaging surveillance from adolescence.

Pregnancy:

Pediatrics:

MEN1 syndrome:

MEN2 / VHL / NF1 / tuberous sclerosis: less commonly associated with carcinoid; more linked to pheo, paraganglioma, pancreatic NETs.

Board pearl: Any patient with two synchronous endocrine neoplasms — e.g., primary hyperparathyroidism + pancreatic NET, or bronchial carcinoid + prolactinoma — warrants MEN1 genetic testing and family screening. Missing the inherited syndrome is a Step 3 favorite trap and a real-world failure of preventive care.

Complications and Adverse Outcomes

— Most common cause of mortality in carcinoid syndrome (20–50% of patients).

— Right-sided plaque deposition → tricuspid regurgitation + pulmonic stenosis → right heart failure.

— Risk factors: high urinary 5-HIAA (>300 mg/24 h), high tumor burden, prolonged disease.

— Treatment: optimize symptom control + diuretics + valve replacement (bioprosthetic preferred) when symptomatic RHF develops; surgery improves survival when timed before severe RV dysfunction.

— Life-threatening release of mediators triggered by surgery, anesthesia, biopsy, embolization, or chemotherapy.

— Manifests as profound BP swings, severe bronchospasm, tachyarrhythmia, altered mental status.

— Prevention with perioperative IV octreotide is mandatory.

— Desmoplastic reaction encases mesenteric vessels → chronic intestinal angina, partial SBO, venous congestion, ascites.

— May require surgical bypass or resection.

— Pellagra from tryptophan diversion: diarrhea, dermatitis (Casal's necklace), dementia.

— Fat-soluble vitamin deficiencies (A, D, E, K) from steatorrhea.

— Vitamin B12 deficiency, magnesium and potassium losses.

— Cachexia and sarcopenia in advanced disease.

— SSA-induced cholelithiasis (~50%), pancreatic enzyme insufficiency.

— PRRT: nephrotoxicity, cytopenias, secondary hematologic malignancy.

— Everolimus: pneumonitis, hyperglycemia, infections.

— Hepatic embolization: post-embolization syndrome, abscess, liver failure if bilobar high-volume in one session.

Carcinoid heart disease (Hedinger syndrome):

Carcinoid crisis:

Mesenteric fibrosis / ischemia:

Nutritional complications:

Treatment-related complications:

Bowel obstruction / perforation from primary tumor or fibrosis.

Psychosocial: chronic diarrhea/flushing impair quality of life; depression and anxiety common; misdiagnosis frustration after years of being told "it's IBS."

Key distinction: Carcinoid heart disease causes right-sided valve disease (TR > PS), unlike rheumatic disease (left-sided MS/MR) or endocarditis on tricuspid (IV drug use). Plaque-like fibrosis on echo + history of flushing/diarrhea = pathognomonic.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Carcinoid crisis — hypotension/labile BP, refractory bronchospasm, arrhythmias.

— Severe dehydration with hemodynamic instability from secretory diarrhea (>10 L/day in extreme cases).

— Decompensated right heart failure with hepatic congestion, hypotension, or hyponatremia.

— Sepsis on background of biliary disease (SSA-induced cholangitis/cholecystitis).

— Severe electrolyte derangements (K <2.5, Mg <1.0) from refractory diarrhea.

— Suspected mesenteric ischemia, partial SBO not resolving with NGT.

— Carcinoid heart disease workup if patient cannot tolerate outpatient diuresis.

— Post-embolization syndrome management, post-PRRT cytopenias with neutropenic fever.

— Medical oncology / NET specialist — within 1–2 weeks of biochemical confirmation.

— Cardiothoracic surgery for symptomatic carcinoid heart disease with NYHA III/IV symptoms.

— Interventional radiology for liver-directed therapy candidacy.

— Endocrinology / genetics if MEN1 suspected.

— Anesthesiology preop consult for any planned surgical or procedural intervention.

— Continuous cardiac monitoring, two large-bore IVs, arterial line.

— IV octreotide 500–1000 mcg bolus, then 50–200 mcg/hr infusion.

— Aggressive IV crystalloid (Ringer's preferred — replace bicarb losses).

— Vasopressin or phenylephrine if pressor needed; avoid epinephrine, norepinephrine, dopamine (catecholamines worsen mediator release).

— Ipratropium nebs for bronchospasm; avoid beta-agonists in active crisis.

— Hydrocortisone 100 mg IV may help.

— Replete K, Mg, Ca; monitor lactate, BNP, troponin.

Immediate ICU admission:

Inpatient admission (non-ICU):

Urgent specialty consultation:

CCS-style management sequence for suspected carcinoid crisis:

CCS pearl: When the test-day patient has a NET going to the OR or interventional suite, the first order is IV octreotide infusion ≥12 hours preoperatively — placing this order before "anesthesia consult" or "type and screen" earns the management point on simulated cases.

Key Differentials — Same-Category Causes (Other Flushing/Diarrhea Syndromes)

— Episodic HTN, palpitations, headache, diaphoresis with pallor (not flushing).

— Catecholamine excess: elevated plasma free metanephrines / 24-h urine metanephrines.

— Adrenal mass on imaging; MIBG or DOTATATE scan for paragangliomas.

— Flushing, pruritus, urticaria pigmentosa, anaphylactoid reactions.

— Elevated serum tryptase, urinary N-methylhistamine.

— Bone marrow biopsy shows mast cell aggregates with KIT D816V mutation.

— Flushing + diarrhea from calcitonin and serotonin.

— Elevated calcitonin and CEA; thyroid nodule on US; part of MEN2.

— Watery diarrhea (>3 L/day, "pancreatic cholera"), hypokalemia, achlorhydria.

— Elevated VIP; pancreatic tail mass on imaging.

— Refractory PUD, secretory diarrhea, elevated gastrin off PPI; pancreatic/duodenal NET.

— Diabetes, weight loss, necrolytic migratory erythema, DVT; elevated glucagon.

— ACTH-secreting bronchial/thymic NET → ectopic Cushing's.

— GHRH-secreting NET → acromegaly with normal pituitary MRI.

Pheochromocytoma / paraganglioma:

Mastocytosis / mast cell activation syndrome:

Medullary thyroid carcinoma (MTC):

VIPoma (Verner-Morrison / WDHA syndrome):

Gastrinoma (Zollinger-Ellison):

Glucagonoma:

Insulinoma: Whipple's triad of hypoglycemia — not a flushing syndrome but a NET differential.

Somatostatinoma: diabetes, cholelithiasis, steatorrhea triad.

Other NET-mimicking endocrine tumors:

Key distinction: Dry flush + diarrhea + right-heart murmur = carcinoid; wet (sweaty) paroxysm + HTN + pallor = pheochromocytoma; flush + urticaria + tryptase elevation = mastocytosis; watery diarrhea + hypoK + achlorhydria = VIPoma. Memorize these 4 phenotype anchors and most NET-style flush stems sort themselves.

Key Differentials — Other-Category Causes (Non-NET Mimics)

— Most common carcinoid mimic in women 45–55.

— Vasomotor flushes with diaphoresis, night sweats, irregular menses, FSH elevated.

— Carcinoid flush is dry, not associated with menstrual irregularity, and not improved by HRT.

— Chronic facial erythema with telangiectasias, papulopustules, ocular involvement.

— Triggered by spicy foods, alcohol, heat — overlap with carcinoid triggers.

— No systemic symptoms (no diarrhea, no murmur, no weight loss).

— Time-locked to ingestion; resolves rapidly; common in East Asian patients.

— Niacin (immediate-release), CCBs (especially amlodipine), nitrates, sildenafil, vancomycin (red-man), cholinergic agents, tamoxifen, opioids.

— Diarrhea is the chief overlap. IBS lacks systemic features; IBD has bloody stools, elevated CRP/fecal calprotectin, endoscopic mucosal inflammation.

— Step 3 trap: years of "IBS" diagnosis in a patient who now has a right-sided murmur — re-open the differential.

Menopause / perimenopause:

Rosacea:

Alcohol-induced flushing / disulfiram reaction / ALDH2 deficiency:

Idiopathic flushing: diagnosis of exclusion; normal 5-HIAA, tryptase, metanephrines.

Medication-induced flushing:

Anxiety / panic disorder: flushing with tachycardia and tremor, but no objective biochemical abnormalities.

Hyperthyroidism: heat intolerance, diarrhea, weight loss — check TSH; flushing is less prominent.

IBS / IBD:

Microscopic colitis: chronic watery diarrhea in older women, biopsy diagnosis — normal-appearing colonoscopy but lymphocytic/collagenous infiltrate.

Bile acid diarrhea (post-cholecystectomy, ileal disease): responds to cholestyramine.

Dumping syndrome (post-gastrectomy/bariatric): postprandial flushing, tachycardia, diarrhea, hypoglycemia 1–3 hours after meal.

Systemic mastocytosis (cross-listed — see chunk 13).

Board pearl: In a postmenopausal woman with "rosacea + IBS," check 24-hour urinary 5-HIAA + echocardiogram before adding another antidepressant or topical metronidazole — Step 3 loves the missed-carcinoid story arc spanning a decade of misdiagnosis.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Long-acting SSA (octreotide LAR 30 mg IM q4 weeks or lanreotide 120 mg deep SC q4 weeks) — indefinite, both symptom and antiproliferative control.

— Short-acting octreotide SC PRN for breakthrough flush/diarrhea, and as rescue before known triggers (anesthesia, dental procedures, stressful events).

— Telotristat ethyl 250 mg TID if diarrhea persists despite SSA.

— Loperamide PRN for breakthrough loose stools.

— Pancreatic enzyme replacement if steatorrhea on SSA.

— Fat-soluble vitamin (ADEK) and B12 supplementation; niacin 50–100 mg daily if pellagra risk.

— Cholecalciferol (vitamin D), calcium.

— Loop diuretic ± aldosterone antagonist for right heart failure.

— Avoid beta-blockers in active flushing (can blunt sympathetic compensation); use cautiously in carcinoid heart disease with arrhythmia.

— Anticoagulation considered for atrial arrhythmias or mechanical valves.

— Avoid ethanol, aged cheeses, smoked/cured meats, fermented foods (tyramine).

— Limit emotional and physical stressors that trigger flushing.

— Sun protection (pellagra dermatitis is photodistributed).

— Smoking cessation — accelerates carcinoid heart disease and worsens bronchial primary outcomes.

— SSRIs/SNRIs (worsen serotonin burden), MAOIs (hypertensive crisis with tyramine), sympathomimetic decongestants, succinylcholine.

— Discuss with all prescribers; flag in EHR.

Long-term medical regimen at discharge / outpatient stabilization:

Cardiac secondary prevention:

Lifestyle and trigger avoidance counseling:

Vaccinations: annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID, RSV if age-appropriate; especially important on PRRT/everolimus.

Drugs to avoid long-term:

Genetic counseling if MEN1 suspected — annual screening for first-degree relatives starting in adolescence.

Step 3 management: At every discharge or outpatient transition, confirm three "S's": SSA injection scheduled, Symptom rescue plan (short-acting octreotide), and Surveillance plan (next echo, next CT/MRI, next 5-HIAA). Discharging a NET patient without these is the typical Step 3 transitions-of-care failure.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Clinic visit every 3 months × first year, then every 3–6 months.

— Biomarkers: 24-hour urinary 5-HIAA + chromogranin A every 3–6 months; trend not absolute value.

— Cross-sectional imaging: CT or MRI of chest/abdomen/pelvis every 3–6 months × 2 years, then every 6–12 months if stable.

— DOTATATE PET/CT at baseline and at suspected progression, not routinely repeated.

— Echocardiogram + NT-proBNP annually; sooner if new murmur, dyspnea, edema, or rising 5-HIAA >300 mg/24 h.

— SSA: annual gallbladder ultrasound, HbA1c if pre-diabetic, B12 yearly, fecal elastase if steatorrhea.

— Everolimus: monthly CBC, CMP, lipids, glucose; baseline + symptomatic chest imaging for pneumonitis.

— Sunitinib: BP every visit (HTN), TSH every 3 months, LFTs, ECG (QT).

— PRRT: CBC monthly × 6 months then quarterly; renal function (CrCl) every 6 months × 2 years.

— Telotristat: LFTs at 1 month, then every 6 months; mood screen.

— Dietitian referral for tyramine/serotonin-rich food avoidance, hydration plan, electrolyte repletion strategy.

— Pulmonary rehab if bronchial primary with chronic respiratory limitation.

— Cardiac rehab if post-valve replacement.

— Physical therapy and resistance training to combat sarcopenia.

— Screen for depression and anxiety annually (PHQ-9, GAD-7); avoid SSRIs — prefer mirtazapine, bupropion, or buspirone if pharmacotherapy needed.

— Support groups (Carcinoid Cancer Foundation, NANETs) improve adherence and QoL.

— Sexual health, fertility preservation discussions (PRRT and alkylators are gonadotoxic).

Routine surveillance schedule (well-differentiated NET on SSA):

Treatment-specific monitoring:

Nutrition and rehab:

Psychosocial counseling:

Advance care planning at each transition; integrate palliative care early — improves both QoL and survival in advanced NETs.

Board pearl: Rising 5-HIAA + worsening dyspnea + new TR murmur = order an echocardiogram urgently for progression of carcinoid heart disease — the most important monitoring trigger to recognize, because earlier valve replacement (before severe RV dysfunction) is the single intervention that most improves survival.

Ethical, Legal, and Patient Safety Considerations

— PRRT uses a radioactive isotope (¹⁷⁷Lu) — patients must understand isolation precautions, contact restrictions with pregnant women and young children for 7 days post-infusion, and small (~2%) lifetime risk of secondary leukemia/MDS.

— Hepatic embolization consent must include risk of carcinoid crisis, hepatic abscess, post-embolization syndrome, and (rarely) liver failure; offer alternatives.

— Valve replacement in advanced carcinoid heart disease: discuss high operative mortality (5–10%) vs natural-history mortality without surgery; bioprosthetic vs mechanical choice tied to anticoagulation feasibility.

— Discharging a patient on monthly depot SSA injections without confirming insurance authorization, home health visit, or clinic injection appointment is a common failure — patients miss doses and develop symptom rebound or carcinoid crisis.

— Medication reconciliation must flag SSRIs, MAOIs, sympathomimetics, succinylcholine as "do-not-prescribe" in the EHR; communicate to primary care and pharmacy.

— Carry an emergency wallet card stating "carcinoid syndrome — give IV octreotide for crisis, avoid catecholamines, avoid morphine/succinylcholine."

— MEN1 cascade testing requires counseling about implications for insurance (GINA protects health but not life/disability), employment, and reproductive planning.

— Pediatric testing of at-risk children is appropriate because surveillance starts in adolescence — distinct from adult-onset cancer genes.

— Cancer diagnosis must be reported to state tumor registry (provider responsibility, usually automated through pathology).

— Radiation exposure tracking for PRRT — institutional radiation safety officer required.

— NETs are best managed at high-volume centers; rural patients face access disparities — telehealth co-management with tertiary centers improves outcomes.

— Long delays to diagnosis disproportionately affect women (misdiagnosed as menopause/IBS) — recognize implicit bias.

— Early palliative care referral improves quality of life and survival; not synonymous with hospice.

Informed consent edge cases:

Transition-of-care safety (high-yield Step 3 theme):

Genetic testing ethics:

Mandatory reporting / regulatory:

Health-systems and equity:

Palliative integration:

Step 3 management: When a NET patient is transferred between facilities, the single most important order to carry forward is the scheduled long-acting SSA dose and the next due date — missing a depot dose risks rapid symptom rebound and intraoperative crisis if surgery is planned.

High-Yield Associations and Rapid-Fire Clinical Facts

Carcinoid syndrome requires hepatic mets for midgut primaries; foregut and lung primaries can cause syndrome without liver involvement.

5-HIAA = serotonin metabolite in urine; chromogranin A = general NET marker (false-positive on PPIs).

Octreotide and lanreotide bind SSTR2/5; need DOTATATE PET to confirm receptor expression.

Most common NET site overall: small bowel (terminal ileum) — classic Step 3 stem.

Most common appendiceal tumor: carcinoid (appendiceal NET).

Appendiceal carcinoid <2 cm at tip → appendectomy alone curative.

Appendiceal carcinoid >2 cm or base involvement → right hemicolectomy.

Hedinger syndrome = right-sided valvular fibrosis from carcinoid.

Pellagra triad: dermatitis, diarrhea, dementia — from tryptophan diversion to serotonin.

Foregut flush = histamine, prolonged, purple, wheal-like; midgut flush = serotonin/kinins, dry pink, brief.

NETTER-1 trial = ¹⁷⁷Lu-DOTATATE for midgut NETs.

PROMID trial = octreotide LAR antiproliferative in midgut.

CLARINET trial = lanreotide antiproliferative across GEP-NETs.

RADIANT trials = everolimus in pancreatic and GI NETs.

MEN1 = 3 P's; foregut carcinoids (thymic, bronchial, gastric type II).

Avoid in carcinoid crisis: catecholamines (epi/norepi), morphine, succinylcholine; use vasopressin/phenylephrine.

Preop prophylaxis: IV octreotide ≥12 hours before surgery.

SSA side effects: gallstones, steatorrhea, hyperglycemia, bradycardia, B12 deficiency.

Telotristat = tryptophan hydroxylase inhibitor for refractory diarrhea.

Gastric NETs: Type I (atrophic gastritis, benign), Type II (MEN1/ZES), Type III (sporadic, aggressive).

Bronchial carcinoid + Cushing's → ectopic ACTH secretion.

Niacin replacement prevents pellagra in chronic carcinoid.

Tyramine triggers: aged cheese, cured meats, fermented foods, red wine.

Anti-fibrotic effect on mesentery → "spoke-wheel" sign on CT.

Board pearl: The single most discriminating physical finding in carcinoid syndrome is dry flushing without diaphoresis — if the stem mentions sweating, look elsewhere (pheo, menopause, hyperthyroidism, anxiety).

Board Question Stem Patterns

Stem 1 — Classic missed diagnosis: 58-year-old woman with 7 years of "IBS" diarrhea, episodic facial flushing attributed to menopause; new TR murmur, hepatomegaly. Next step? → 24-hour urinary 5-HIAA. Then DOTATATE PET, echo, refer to NET center.

Stem 2 — Chromogranin A pitfall: Patient on omeprazole found to have elevated CgA on workup of vague abdominal pain. Next step? → Stop PPI for 2 weeks and recheck, not initiate NET imaging.

Stem 3 — Intraoperative crisis: During exploratory laparotomy for small-bowel mass, patient develops profound hypotension, bronchospasm, flushing. Best next step? → IV octreotide bolus and infusion, IV fluids, vasopressin if pressor needed. Avoid epinephrine.

Stem 4 — Foregut vs midgut: Bronchial mass with prolonged purple flushing, lacrimation, normal 5-HIAA. Diagnosis? → Foregut bronchial carcinoid (histamine-mediated, low serotonin output).

Stem 5 — Appendiceal NET: Incidental 1.2-cm tumor at appendix tip after appendectomy. Next step? → No further therapy; routine surveillance.

Stem 6 — Right-heart failure: NET patient with worsening peripheral edema, elevated JVP, pulsatile liver. Next step? → Echocardiogram + NT-proBNP; refer cardiothoracic surgery if symptomatic severe TR.

Stem 7 — Preop planning: Patient with known carcinoid syndrome scheduled for elective cholecystectomy. First order? → IV octreotide infusion starting ≥12 hours preoperatively.

Stem 8 — MEN1 recognition: Patient with primary hyperparathyroidism and a pancreatic mass; gastrin elevated. Next step? → MEN1 genetic testing + screen for pituitary adenoma.

Stem 9 — Pellagra: NET patient with photodistributed dermatitis on neck, glossitis, confusion. Treatment? → Niacin supplementation.

Stem 10 — SSA failure: Patient on octreotide LAR with persistent 6 stools/day. Add? → Telotristat ethyl.

Stem 11 — Cholelithiasis on SSA: New RUQ pain, ultrasound shows gallstones. Management? → Cholecystectomy (and continue SSA).

Stem 12 — PRRT eligibility: Progressive midgut NET on SSA, DOTATATE-avid, CrCl 70. Best next therapy? → ¹⁷⁷Lu-DOTATATE (Lutathera).

Step 3 management: When the stem includes flushing + diarrhea + right-sided murmur, the answer chain is essentially fixed: 5-HIAA → DOTATATE PET → SSA + echo + NET referral. Memorize this sequence cold.

One-Line Recap

Carcinoid syndrome is the systemic flushing-diarrhea-right-heart-disease constellation caused by a well-differentiated neuroendocrine tumor releasing serotonin and vasoactive mediators past hepatic first-pass metabolism, diagnosed by 24-hour urinary 5-HIAA plus ⁶⁸Ga-DOTATATE PET/CT, and managed with long-acting somatostatin analogs as the backbone, perioperative IV octreotide prophylaxis to prevent crisis, and an annual echocardiogram to detect Hedinger valvular disease before irreversible right heart failure.

Diagnose: 24-h urinary 5-HIAA (avoid serotonin-rich foods and interfering drugs); chromogranin A as adjunct trend (false-positive on PPIs/renal failure); DOTATATE PET to localize and confirm SSTR-2 expression; tissue Ki-67 to grade (G1 <3%, G2 3–20%, G3 >20%).

Treat: Long-acting octreotide or lanreotide for symptoms AND antiproliferation; add telotristat for refractory diarrhea; PRRT with ¹⁷⁷Lu-DOTATATE for progressive SSTR-positive disease; liver-directed therapy or hepatic debulking for hepatic-dominant burden; cisplatin/etoposide reserved for high-grade NEC.

Prevent crisis: IV octreotide ≥12 hours before any surgery, anesthesia, biopsy, or embolization; avoid catecholamines, morphine, succinylcholine, SSRIs, sympathomimetics in carcinoid patients.

Surveil: Annual echocardiogram + NT-proBNP (Hedinger disease is the leading killer), quarterly 5-HIAA and CgA trends, semiannual cross-sectional imaging, gallbladder ultrasound and HbA1c monitoring on SSAs, and consider MEN1 testing in any patient with multiple endocrine neoplasms.

Step 3 management: The recurring exam choreography is flushing + diarrhea + right-sided murmur → 5-HIAA → DOTATATE PET → start long-acting SSA → baseline echo → refer to high-volume NET center, then layer perioperative octreotide and trigger-avoidance counseling at every transition of care.